Parul University Wins a Government Patent for a Homoeopathic Medicated Sanitiser!

Patent No. 583580 recognises a skin-friendly alternative to alcohol-based sanitisers and shows what interdisciplinary research at Parul University can produce!

The Government of India has granted Parul University Patent no. 583580 for a Homoeopathic Medicated Sanitiser, developed by two of its own faculty researchers. The application was filed in April 2024, and the patent was granted in March 2026, jointly owned by the University and its two inventors.

It’s a small, specific piece of news. But it’s worth sitting with for a moment, because it says something bigger about how research actually moves from an idea to a government-verified result, and about where the line sits between “patented” and “proven.”

The Patent, in Plain Terms

Here’s what’s on the record, straight from the Patent Office:

• Invention: Homoeopathic Medicated Sanitiser
• Patent number: 583580
• Application number: 202421028067
• Filed: 5 April 2024
• Granted: 17 March 2026, entered in the Register of Patents the same day
• Term: 20 years from the filing date, renewable under the Patents Act, 1970
• Patentees: Parul University (Parul Institute of Homoeopathy and Research), Dr. Suraj Singh Bhadoria (Parul Institute of Homoeopathy and Research), and Dr. Janki Patel (Parul Institute of Pharmacy and Research)

The Problem the Invention Tries to Solve

Anyone who lived through the last few years of near-constant hand sanitising knows the side effect: dry, cracked, irritated skin. Alcohol-based and chemical sanitisers are effective against microbes, but repeated use throughout the day, at home, at work, and in hospitals takes a toll on the skin barrier.

That’s the gap the research team set out to address. Their goal was a formulation that keeps the antimicrobial effectiveness of a sanitiser while being gentler on skin that gets sanitised dozens of times a day. According to the researchers, their own laboratory studies during development pointed to antibacterial activity alongside good skin compatibility. It’s worth being precise about what that means: these are the institutes’ own reported findings from their development work, not an independent clinical verdict. They describe why the team moved forward with the formulation — not a final word on its performance.

Two Institutes, One Invention

What makes this patent interesting isn’t just the product; it’s who built it together.

Dr. Suraj Singh Bhadoria, of the Parul Institute of Homoeopathy and Research, brought the homoeopathic formulation expertise: selecting and preparing the ingredients at the core of the sanitiser.

Dr. Janki Patel, of the Parul Institute of Pharmacy and Research, took those ingredients and worked them into an actual sanitiser composition, then carried the formulation through lab testing.

That pairing of a homoeopathy specialist and a pharmaceutical scientist, working across two institutes of the same university, is really the substance of the achievement. The inventors describe using ultra-high dilution, a technique associated in homoeopathic practice with effects at very small scales. It’s fair to flag here that the science behind ultra-high dilution remains genuinely debated in the wider research community; this is presented as the inventors’ stated method, not as an established mechanism. What the patent grant does confirm is that the Patent Office examined the resulting composition and found it novel, inventive, and industrially applicable.

The process itself wasn’t a rubber stamp. The application went through examination under the Patents Act, a hearing in February 2026, and a grant the following month, on a single claim. Every step of that is documented in the Patent Office record, which is a big part of why this is verifiable rather than just asserted.

What a Patent Actually Certifies (and What It Doesn’t)

This is the part that matters most, especially for anything touching health products.

A patent granted under the Patents Act, 1970, certifies three specific things: that an invention is novel, that it involves an inventive step, and that it is capable of industrial application. That’s it. That’s the legal bar.

A patent does not certify that a product is clinically effective, that it’s safe for medical use, or that it can be sold as-is. Those are separate regulatory questions entirely, governed by different bodies. The patent documentation itself notes that large-scale manufacture and commercialisation would need to conform with all applicable regulations before this could reach a shelf.

A patent certifies novelty, inventive step and industrial applicability. It is not a licence to sell, nor proof of a cure.

So the honest way to describe this moment is: Parul University now holds a verified, government-granted intellectual property right over a novel invention. Whether and how that invention becomes an actual product on the market is a separate, later question.

Why It Matters Beyond This One Product!

This truly shows Parul University is carrying an idea through the full arc of translational research lab concept to formally examined, granted IP, across disciplinary lines rather than within a single department.

It also sits inside a larger national conversation. The invention falls within India’s AYUSH framework for traditional systems of medicine, at a moment when there’s active policy interest in indigenous, locally developed healthcare technologies. The research team frames their work as part of that broader push.

Dr. Geetika Madan Patel, Vice President of Parul University, put the achievement in that context:

“The innovation reflects the institution’s commitment to research excellence and its ability to bridge traditional knowledge with modern science for societal benefit.”

Where It Could Go From Here!

The research team envisions the formulation being used anywhere frequent sanitising happens and skin tolerance is a real concern, such as homes, schools, hospitals, workplaces, and public spaces, with healthcare and sanitation staff as the most exposed and most frequent users.

As for what’s next, the team has laid out some directions: extending the formulation’s antimicrobial range, running larger studies, and exploring related hygiene products built on the same principles. The patent also opens the door to industry partnerships and eventual commercialisation.

All of that deserves the same caveat as everything else here: these are stated intentions, not accomplished results. What’s actually been verified, right now, is the patent itself, a granted government right over a novel invention. The path from there to a tested, approved, market-ready product is real, but it hasn’t been walked yet.

Interested in where research like this happens? Explore what studying and researching at Parul University looks like.